Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
January-2018 Volume 17 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2018 Volume 17 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3

  • Authors:
    • Shuping You
    • Yun Guan
    • Weihong Li
  • View Affiliations / Copyright

    Affiliations: Department of Anorectal Surgery, Jingmen No. 2 People's Hospital, Jingmen, Hubei 448000, P.R. China, Imaging Center, The Affiliated Central Hospital of Jingmen No. 2 People's Hospital, Jingchu University of Technology, Jingmen, Hubei 448000, P.R. China
  • Pages: 1065-1070
    |
    Published online on: November 3, 2017
       https://doi.org/10.3892/mmr.2017.7943
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

To investigate the inhibitory effects of DEK/insulin‑like growth factor II mRNA binding protein 3 (IMP3) on epithelial‑mesenchymal transition (EMT) in colorectal carcinoma cells. SW620 and SW480 cell lines were selected. DEK‑interfering lentivirus was transfected to knockdown DEK expression. Subsequently, MTT assays and flow cytometry were utilized to measure cell viability, and apoptosis, respectively. Cell invasion was detected using a Transwell assay. Quantitative polymerase chain reaction and western blot analysis were used to detect the expression of E‑cadherin, vimentin, and matrix metalloproteinase (MMP)‑9. Compared with the blank control, cells transfected with DEK‑interfering lentivirus demonstrated a remarkable reduction in cell viability (P<0.05). The apoptotic rate in the DEK‑interfering lentivirus group was significantly enhanced compared with the blank control group (P<0.05). In the DEK‑interfering lentivirus group, the expression of E‑cadherin was significantly elevated (P<0.05), while the expression of vimentin and MMP‑9 were significantly reduced in both cell lines (P<0.05). The results of the present study demonstrated that EMT of colorectal carcinoma cells was partially mediated by DEK, which likely affected the invasive ability of colorectal carcinoma cells. In addition, cell proliferation and apoptosis were susceptible to DEK silencing. The current study has provided experimental evidence for the treatment of colorectal carcinoma using DEK silencing.

Introduction

Colorectal carcinoma is one of the most common malignant tumors (1) with obviously increased metastasis and mortality in its advanced stage (2). Insulin-like growth factor II mRNA binding protein 3 (IMP3) is a kind of binding protein, which can specifically recognize mRNA sequence. It is also an oncofetal protein and expressed in a number of malignant tumors, related to the advances in tumor invasion. Invasion and metastasis of tumor cells might be modulated by the expression of IMP3 (3–5). Indeed, the members of IMPs family-IMP3 and IMP1 are applied as vital biological invasion markers for pancreatic cancer (6). Moreover, IMP3 expression in different stages of colorectal carcinoma was discrepant and IMP3 was expected to be a new target in the treatment of colorectal carcinoma (7).

As a pro-oncogene, DEK not only regulates cell senescence and apoptosis (8) but also the transcriptional regulator of retinoblastoma tumor suppressor protein (Rb)/E2F, which is often disturbed in colorectal carcinoma (9). DEK protein is highly-expressed in tumors and can be easily detected by commercial antibodies. Therefore, it holds great promise to be utilized as a tumor diagnostic marker. Benign and malignant melanoma could be easily identified according to the expression level of DEK (10). Moreover, DEK expression in undifferentiated cells was much higher than that in mature cells (11), which could be used to assess the differentiative capacity of tumor cells. In the present study, colorectal carcinoma cell lines SW620 and SW480 were selected. The cells were transfected with DEK interfering lentivirus and empty carrier, respectively. Consequently, effects of DEK silence on the cell viability, apoptosis, invasion and epithelial-mesenchymal transition (EMT) were detected.

Materials and methods

Cell culture and transfection

Colorectal carcinoma cell lines SW620 and SW480 (Shanghai Cell Bank of Chinese Academy of Science, China) were cultured in dulbecco minimum essential medium (DMEM) (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) and 100 U/ml penicillin-streptomycin (Sigma, Ronkonkoma, NY, USA) in 5% CO2 at 37°C.

The experiment was divided into three groups: blank control, lentivirus encoding NC-siRNA, and lentivirus encoding DEK siRNA. The cells at 70% confluence were transfected with empty carrier and DEK interfering lentivirus (GenePharma, Shanghai, China), respectively. After 6 h, the medium were replaced with fresh DMEM medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% FBS. The cells were incubated in CO2 incubator at 37°C for 48 h. Finally, the expression levels of DEK and IMP3 in mRNA and protein levels were detected by quantitative real-time polymerase chain reaction (QRT-PCR) and western blot, respectively.

MTT assay

Colorectal carcinoma SW620 cells were seeded in 96-well plates. After transfection of 24, 48, 72 and 96 h, 20 µl medium with MTT (final concentration: 5 mg/ml) (Gibco; Thermo Fisher Scientific, Inc.) was added. After additional 4-h incubation in CO2 incubator at 37°C, the medium were discarded. DMSO (150 µl) (Sigma, USA) was added into each well and the plates were shaken to dissolve formazan sufficiently. The absorbance at 560 nm was recorded by a microplate reader (Thermo Fisher Scientific, Inc.). The optical density (OD) values represented cell viability.

Flow cytometry

Colorectal carcinoma SW620 cells were seeded in 6-well plates. After transfection of 48 h, the cells were collected after digestion by trypsin (Gibco; Thermo Fisher Scientific, Inc.). Under the protection from light, the cells were incubated with Annexin V-FITC/PI (C1062, Beyotime, Ningbo, China) for 30 min. Next, apoptosis was detected by flow cytometry (BD Company, Franklin Lakes, NJ, USA) within 1 h.

Transwell assay

After 48 h transfection, the cells were digested and seeded into the upper chamber of transwell. The lower chamber only contained DMEM medium. After 48 h incubation in CO2 incubator at 37°C, the down chamber was taken out and fixed with polyformaldehyde. After staining with crystal violet, inverted microscopy was used to count the cell numbers in five fields. The average number represented the capacity of cell invasion.

Quantitative real-time polymerase chain reaction (QRT-PCR)

After viral transfection, mRNA in different groups was extracted using a TRIzol assay kit (Baosheng Science & Technology Innovation Co, Ltd., Shanghai, China). mRNA was transcribed into cDNA according to the reverse transcription kit (639522, Takara Biotechnology Co., Ltd., Dalian, China) and fluorescence quantitative PCR was utilized to detect the expression level of the targeted genes using cDNA as template. The relevant expression level of E-cadherin, Vimentin and MMP-9 were normalized to β-actin. The primer sequences were listed as follows:

DEK-F: AAA CCT AGC CAG CTT CAC GA; DEK-R: AGG CCC AAC TGC AGA GAA AC; E-cadherin-F: CGC CGA GAG CTA CAC GTT CA; E-cadherin-R: TGT CGA CCG GTG CAA TCT TC; Vimentin-F: TGC GTG AAA TGG AAG AGA ACT; Vimentin-R: TGC GTG AAA TGG AAG AGA ACT; IMP3-F: GCG CTG CTG GAC AAG CTG TAT G; IMP3-R: AGG ACG AGG CCG TGA CGA A; MMP-9-F: CAT CTT CCA AGG CCA ATC C; MMP-9-R: CCA TCA CCG TCG AGT CAG C; β-actin-F: ACT CTT CCA GCC TTC CTT C, β-actin-R: ATC TCC TTC TGC ATC CTG TC.

Western blot analysis

Cell lysis solution was added into each group of cells. After 30 min dissociation at 4°C, the solutions were centrifuged at 11,670 g for 10 min. The supernatant was collected, which contained total protein. The protein concentration was measured by BCA kit (Beyotime). 20 µg protein in each group was loaded for gel electrophoresis and the membrane was transferred by wet methods. The antibodies, including anti-DEK (1:1,000, catalogue no. ab221545), anti-IMP3 (1:1,000, catalogue no. ab177477), anti-E-cadherin (1:1,000, catalogue no. ab1416), anti-Vimentin (1:1,000, catalogue no. ab8978; Abcam, Cambridge, UK), anti-MMP-9 (catalogue no. ab73734; 1:1,000; Abcam) and β-actin (1:1,000; catalogue no. AF0003, Beyotime Institute of Biotechnology, Shanghai, China) were incubated with nitrocellulose membranes overnight at 4°C. Next, the secondary antibody (1:100; catalogue nos. ab131368; Abcam) was added and co-incubated for 1–2 h at room temperature. ECL exposure liquid droplet (catalogue no. RPN2133; GE Healthcare Life Sciences, Chalfont, UK) was added on the membrane. In the end, the membrane was used for exposure utilizing gel imaging system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Grey density was analyzed using Quantity One analysis software v1.4.6 (Bio-Rad Laboratories, Inc.).

Statistical analysis

The data were presented as mean ± standard deviation (SD), and analyzed using SPPSS 17.0. Significant differences were calculated by t-test, where P<0.05 was considered to indicate a statistically significant difference.

Results

DEK silence down-regulates IMP3 expression and influences EMT

As shown in Fig. 1, the expression of DEK and IMP3 in mRNA and protein levels in DEK interfering lentivirus group was reduced significantly compared to the blank control group (P<0.05). By contrast, empty virus did not affect DEK and IMP3 expression in SW620 cells. Later, we assessed the effects of DEK silence on EMT. As shown in Fig. 2A, there was a significant enhancement in the mRNA level of E-cadherin and decrease in the mRNA level of Vimentin and MMP-9 when SW620 cells were treated with DEK interfering lentivirus (vs. blank control, P<0.05). Consistently, DEK silence also affected E-cadherin, Vimentin and MMP-9 protein expression in the similar trend (Fig. 2B). We also confirmed the effects of DEK silence on EMT in SW480 cells. DEK interfering lentivirus also decreased DEK and IMP3 mRNA expression (Fig. 3A). Interestingly, DEK silence also elevated E-cadherin and mitigated Vimentin and MMP-9 expression in both mRNA and protein levels (Fig. 3B and C).

Figure 1.

Expression level of DEK and IMP3 in cells of different groups. (A) mRNA expression; (B) Protein expression. *P<0.05 compared with control.

Figure 2.

Effects of DEK silence on EMT of SW620 cells. (A) mRNA expression; (B) Protein expression. *P<0.05 compared with control.

Figure 3.

Effects of DEK silence on EMT of SW480 cells. (A) mRNA expression of DEK and IMP3; (B) mRNA expression of E-cadherin, MMP-9 and vimentin; (C) Protein expression of E-cadherin, MMP-9 and vimentin. *P<0.05 compared with control.

DEK silence inhibits proliferation of colorectal carcinoma cells

As shown in Fig. 4, transfection of DEK interfering virus for 24, 48, 72, 96 h caused a drastic decrease in the percentage of the cell viability of SW620 cells in DEK interfering lentivirus group (vs. blank control, P<0.05).

Figure 4.

Effects of DEK silence on cell viability of colorectal carcinoma cells. *P<0.05 compared with control.

DEK silence promotes apoptosis of colorectal carcinoma cells

Compared with the blank control group, the apoptotic rate of cells in DEK interfering lentivirus group was significantly elevated (vs. blank control, P<0.05, Fig. 5).

Figure 5.

Effects of DEK silence on apoptosis of colorectal carcinoma cells. (A) Representative images and (B) quantification of apoptosis. *P<0.05 compared with control.

DEK silence inhibits cell invasion of colorectal carcinoma cells

As shown in Fig. 6, transfection of DEK interfering lentivirus significantly decreased the cell invasion ability (vs. blank control, P<0.05).

Figure 6.

Effects of DEK silence on cell invasion of colorectal carcinoma cells. (A) Representative images and (B) quantification of cell invasion. *P<0.05 compared with control.

Discussion

IMP3 is a major component involved in epithelial-mesenchymal transition (7). Since IMP3 is a highly-conserved protein with the potential to bind to mRNA sequence. It is a main contributor in promoting embryonic development as a member of IMP family. Moreover, the expression level of IMP3 is obviously higher in embryonic period (6). In pathological conditions, the expression of IMP3 is elevated in various malignant tumors (7). In addition, there were researches demonstrating that the possibility of distant carcinoma metastasis was associated with unfavorable prognosis (12–15). DEK is a new member of DNA topology adjustment factors (10). The expression level of DEK is not only apparently related to cell proliferation and apoptosis but also affects the migration and invasion of colorectal carcinoma cells (16,17).

In this study, we applied colorectal carcinoma SW620 and SW480 cells as the cell models and constructed DEK interfering lentivirus. Once DEK was silenced, IMP3 expression was also reduced remarkably. These data indicated that DEK and IMP3 were associated in colorectal carcinoma. EMT is featured by the decrease of E-cadherin and increase of Vimentin (18). The up-regulation of E-cadherin expression can inhibit the invasion and metastasis of tumors, while down-regulation of E-cadherin is related to enhancement of invasion and metastasis (19,20). The invasion ability of tumor cells was inhibited after vimentin silence (21). Considering its high expression in various epithelial tumors, vimentin was thought to affect malignant degree of tumor cells (22). The aim of our study was to explore the regulatory effect of DEK/IMP3 pathway on EMT. The expression level of DEK protein was decreased by transfecting with DEK interfering lentivirus. Our data showed that cell invasion of colorectal carcinoma cells could be inhibited as a result of transfection of DEK interfering lentivirus. Cell morphology changed from interstitial-like spindle cells to epithelioid cells. Compared to the blank control group, the expression level of EMT-related markers E-cadherin was enhanced obviously, while the expression level of vimentin and MMP-9 were apparently down-regulated. It is possible that the expression of DEK was positively associated with vimentin and MMP-9 expression, while it was negatively correlated with E-cadherin expression. This result indicated that DEK played important roles in the regulation of epithelial mesenchymal transition in colorectal carcinoma. Consistently, interference of IMP3 could also significantly up-regulate the expression of E-cadherin in hepatocellular carcinoma (23).

Silence of DEK also decreased the invasion ability, reduced the cell viability and triggered apoptosis. Therefore, DEK played a vital role in regulating the invasion, viability and apoptosis of colorectal carcinoma cells. As demonstrated previously, DEK knockout could also cause apoptosis of cervical cancer cells. The possible mechanism was through p53 dependent apoptosis (24). In addition to the regulation of anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1), DEK also regulates apoptosis (10). Liu et al demonstrated that silence of DEK contributed to apoptosis and senescence of cervical cancer cells (18).

In conclusion, our research demonstrated a regulatory mechanism of DEK on EMT of colorectal carcinoma cells which would finally influence the invasion of colorectal carcinoma cells. Our research provided theoretical guidance for the treatment of colorectal carcinoma.

References

1 

Bordonaro M and Lazarova DL: CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer. Word J Gastroenterol. 21:8238–8248. 2015. View Article : Google Scholar

2 

Wang J, Wang X, Lin S, Chen C, Wang C, Ma Q and Jiang B: Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One. 8:e705192013. View Article : Google Scholar : PubMed/NCBI

3 

Okada K, Fujiwara Y, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Takahashi T, Mori M and Doki Y: Oncofetal protein, IMP3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J Surg Oncol. 105:780–785. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G and Peng Z: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Perak Beljan R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V and Peric M: IMP3 can predict aggressive behaviour of lung adenocarcinoma. Diagn Pathol. 7:1652012. View Article : Google Scholar : PubMed/NCBI

6 

Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL and Dresser K: KOC (K honlology domain containing protein overexpressed in cancer): A novel molecular maker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 29:188–195. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Kumara Shantha H, Kirchoff D, Caballero OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ, Cordon-Cardo C and Whelan RL: Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience. 2:607–614. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Riveiro-Falkenbach E and Soengas MS: Control of tumorigenesis and chenoresistance by the DEK oncogene. Clin Cancer Res. 16:2932–2938. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Huang L, Xu Y, Cai G, Guan Z and Cai S: Downregulation of S100A4 expression by RNA interference suppresses cell growth and invasion in human colorectal cancer cells. Oncol Rep. 27:917–922. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM and Soengas MS: Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69:6405–6413. 2009. View Article : Google Scholar : PubMed/NCBI

11 

Oyarzo MP, Lin P, Glassman A, Bueso-Ramos CE, Luthra R and Medeiros LJ: Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol. 122:348–358. 2004. View Article : Google Scholar : PubMed/NCBI

12 

Lederer M, Bley N, Schleifer C and Hüttelmaier S: The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 29:3–12. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Bell JL, Wächter K, Mühleck B, Pazaitis N, Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Park JY, Choe M, Kang Y and Lee SS: IMP3, a promising prognostic marker in clear cell renal cell carcinoma. Korean J Pathol. 48:108–116. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Wang L, Li HG, Xia ZS, Lü J and Peng TS: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: A retrospective study. Chin Med J (Engl). 123:3554–3558. 2010.PubMed/NCBI

16 

Lin L, Piao J, Ma Y, Jin T, Quan C, Kong J, Li Y and Lin Z: Mechanisms underlying cancer growth and apoptosis by DEK overexpression in colorcetal cancer. PLoS One. 9:e1112602014. View Article : Google Scholar : PubMed/NCBI

17 

Lin L, Piao J, Gao W, Piao Y, Jin G, Ma Y, Li J and Lin Z: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13:3662013. View Article : Google Scholar : PubMed/NCBI

18 

Liu K, Feng T, Liu J, Zhong M and Zhang S: Silencing of the DEK gene induces apoptosis and senescence in CaSki cervical carcinoma cells via the up-regulation of NF-κB p65. Biosci Rep. 32:323–332. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 4:118–132. 2004. View Article : Google Scholar : PubMed/NCBI

20 

Oliveras-Ferraros C, Corominas-Faja B, Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM, López-Bonet E, Martin ÁG and Menendez JA: Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle. 11:4020–4032. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Sarkar FH, Li Y, Wang Z and Kong D: Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI

22 

Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH and Hsu HC: RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 48:1118–1127. 2008. View Article : Google Scholar : PubMed/NCBI

23 

Chen C, Wang FH, An X, Luo HY, Wang ZQ, Liang Y, Zhang L and Li YH: Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 71:371–378. 2013. View Article : Google Scholar : PubMed/NCBI

24 

Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H and Wells SI: Apoptosis inhibition by the human DEK oncoprotein involves interfer-ence with p53 functions. Mol Cell Biol. 26:7506–7519. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
You S, Guan Y and Li W: Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3. Mol Med Rep 17: 1065-1070, 2018.
APA
You, S., Guan, Y., & Li, W. (2018). Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3. Molecular Medicine Reports, 17, 1065-1070. https://doi.org/10.3892/mmr.2017.7943
MLA
You, S., Guan, Y., Li, W."Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3". Molecular Medicine Reports 17.1 (2018): 1065-1070.
Chicago
You, S., Guan, Y., Li, W."Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3". Molecular Medicine Reports 17, no. 1 (2018): 1065-1070. https://doi.org/10.3892/mmr.2017.7943
Copy and paste a formatted citation
x
Spandidos Publications style
You S, Guan Y and Li W: Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3. Mol Med Rep 17: 1065-1070, 2018.
APA
You, S., Guan, Y., & Li, W. (2018). Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3. Molecular Medicine Reports, 17, 1065-1070. https://doi.org/10.3892/mmr.2017.7943
MLA
You, S., Guan, Y., Li, W."Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3". Molecular Medicine Reports 17.1 (2018): 1065-1070.
Chicago
You, S., Guan, Y., Li, W."Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3". Molecular Medicine Reports 17, no. 1 (2018): 1065-1070. https://doi.org/10.3892/mmr.2017.7943
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team